All In Biotech

Drug Trial Radar · NCT05420922

Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC

Efficacy and Safety of Immune Checkpoint Inhibitors (ICIs) and Tyrosine Kinase Inhibitors (TKIs) Therapy for Hepatocellular Carcinoma (HCC):a Multicenter, Retrospective Study on the Real-world in China

Last checked: Nov 20, 2026Latest source record: Jun 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

2,000

Planned (sponsor's estimate)

Start

Nov 1, 2021

Primary completion

Aug 30, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Tongji HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 15, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously threatens the lives and health of the people. The investigators establish multi-center, retrospective research methods, collecting the data of HCC treatment with system treatment (ICIs and TKIs) plus or without local treatment in the last 3 years, comprehensive assessment of their efficacy and safety, explore whether the efficacy of system treatment combination local treatment showed better effect compared with system or local monotherapy. Our study will find a new way to improve the prognosis of HCC patients.

Conditions

  • Hepatocellular Carcinoma
  • Programmed Cell Death 1
  • Effects of Immunotherapy

Interventions

  • Lenvatinib Oral ProductDrug

    Lenvatinib or Sorafenib

  • PD-1 inhibitorDrug

    Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1

  • Local treatmentProcedure

    Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The objective response rate (ORR)Time frame: 8 weeks
  2. The overall survival (OS)Time frame: 12 months
  3. The treatment-related adverse events (TRAEs)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.